DO IMPORTANT DRUGS REACH THE MARKET SOONER

被引：70

作者：

DRANOVE, D ^{[1
]}

MELTZER, D ^{[1
]}

机构：

[1] BRIGHAM & WOMENS HOSP,BOSTON,MA 02115

来源：

RAND JOURNAL OF ECONOMICS | 1994年 / 25卷 / 03期

关键词：

D O I：

10.2307/2555769

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

Since the Food and Drug Administration (FDA) Amendments of 1962, the average time from a drug's first worldwide patent application to its approval by the FDA has risen from 3.5 to 13.5 years. FDA policies and manufacturers' incentives suggest that more important drugs may have reached the market sooner. To test this, we develop measures of ''time to approval'' and ''importance,'' and determine how the latter affects the former. Our results indicate that more important drugs are developed and approved more rapidly than less important drugs. These results imply that the costs of approval lags have probably been overstated and challenge estimates of the returns to research and development in the pharmaceutical industry.

引用

页码：402 / 423

页数：22

共 33 条

[11]

Greene William H, 1990, LIMDEP VERSION 5 1

[12]

Hansen R, 1979, ISSUES PHARM EC

[13] RESEARCH EXPENDITURES AND THE DISCOVERY OF NEW DRUGS [J].